Two new analyses of data from more than 10,000 heart attack survivors worldwide were presented at a recent meeting. Scientists assessed whether the anti-inflammatory therapy canakinumab reduced rates of major adverse cardiovascular events and co-morbidities among high-risk atherosclerotic patients with chronic kidney disease (CKD) or those with pre-diabetes/diagnosed type 2 diabetes, respectively.